Suppr超能文献

相似文献

2
Relevance of Plasma Matrix Metalloproteinase-9 for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation.
Transplant Cell Ther. 2021 Sep;27(9):759.e1-759.e8. doi: 10.1016/j.jtct.2021.06.006. Epub 2021 Jun 12.
5
Outcomes of lung transplantation after allogeneic hematopoietic stem cell transplantation.
Biol Blood Marrow Transplant. 2014 Aug;20(8):1169-75. doi: 10.1016/j.bbmt.2014.04.008. Epub 2014 Apr 13.
6
Characterization of localized macrophages in bronchiolitis obliterans after allogeneic hematopoietic cell transplantation.
Int J Hematol. 2021 Dec;114(6):701-708. doi: 10.1007/s12185-021-03214-7. Epub 2021 Sep 7.
8
Blood CD9 B cell, a biomarker of bronchiolitis obliterans syndrome after lung transplantation.
Am J Transplant. 2019 Nov;19(11):3162-3175. doi: 10.1111/ajt.15532. Epub 2019 Aug 21.
10
Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung.
Biol Blood Marrow Transplant. 2015 Jun;21(6):1127-31. doi: 10.1016/j.bbmt.2015.02.006. Epub 2015 Feb 14.

引用本文的文献

3
A phase 2 multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic HCT.
Blood Adv. 2025 Jan 28;9(2):244-253. doi: 10.1182/bloodadvances.2024014000.
4
Clinical impact of airflow obstruction after allogeneic hematopoietic stem cell transplantation.
Int J Hematol. 2024 Oct;120(4):501-511. doi: 10.1007/s12185-024-03831-y. Epub 2024 Aug 27.
6
Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants.
Front Immunol. 2024 Feb 16;15:1327035. doi: 10.3389/fimmu.2024.1327035. eCollection 2024.
9
Risk Factors for Bronchiolitis Obliterans Syndrome after Initial Detection of Pulmonary Impairment after Hematopoietic Cell Transplantation.
Transplant Cell Ther. 2023 Mar;29(3):204.e1-204.e7. doi: 10.1016/j.jtct.2022.12.001. Epub 2022 Dec 9.
10
Current Definitions and Clinical Implications of Biomarkers in Graft-versus-Host Disease.
Transplant Cell Ther. 2022 Oct;28(10):657-666. doi: 10.1016/j.jtct.2022.07.008. Epub 2022 Jul 11.

本文引用的文献

1
Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant. 2016 Apr;22(4):710-716. doi: 10.1016/j.bbmt.2015.10.009. Epub 2015 Oct 22.
2
Precision medicine--personalized, problematic, and promising.
N Engl J Med. 2015 Jun 4;372(23):2229-34. doi: 10.1056/NEJMsb1503104. Epub 2015 May 27.
5
Is there new hope for therapeutic matrix metalloproteinase inhibition?
Nat Rev Drug Discov. 2014 Dec;13(12):904-27. doi: 10.1038/nrd4390. Epub 2014 Nov 7.
6
An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome.
Eur Respir J. 2014 Dec;44(6):1479-503. doi: 10.1183/09031936.00107514. Epub 2014 Oct 30.
7
Pathway and network analysis in proteomics.
J Theor Biol. 2014 Dec 7;362:44-52. doi: 10.1016/j.jtbi.2014.05.031. Epub 2014 Jun 6.
8
Obliterative bronchiolitis.
N Engl J Med. 2014 May 8;370(19):1820-8. doi: 10.1056/NEJMra1204664.
10
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.
N Engl J Med. 2013 Aug 8;369(6):529-39. doi: 10.1056/NEJMoa1213299.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验